Kenota (formerly ExVivo Labs)

Kenota Health (formerly ExVivo Labs) is a Canadian diagnostics company developing point-of-care immunological testing systems that enable rapid and accurate detection of antibodies in blood samples. Founded in 2014 by Moufeed Kaddoura and headquartered in Kitchener, Ontario, the company's platform is designed to test for multiple diseases and conditions — with an initial focus on allergy testing in humans — using a simple finger-prick blood sample that can be analyzed on-site or off-site without the complexity of traditional laboratory equipment. By eliminating the need for venipuncture and lengthy lab turnaround times, Kenota aims to make advanced immunological testing accessible at the primary care and point-of-care level. The company targets healthcare providers seeking faster, decentralized diagnostic tools. Kenota has raised $16.3 million in total funding across four rounds, including a $9 million Series A in December 2020, with investors including Y Combinator, Draper Associates, 1517 Fund, OS Fund, BoxOne Ventures, Cur8 Capital, and the Business Development Bank of Canada. The company's website (kenota.com) now redirects, suggesting a possible rebrand or pivot in its commercial positioning.